In vivo presynaptic control of dopamine release in the cat caudate nucleus—II. Facilitatory or inhibitory influence ofl-glutamate

doi:10.1016/0306-4522(86)90124-7

Neuroscience

Volume 19, Issue 4, December 1986, Pages 1081-1090

https://doi.org/10.1016/0306-4522(86)90124-7 Get rights and content

Abstract

The local effects of various concentrations ofl-glutamate (from 10⁻⁸ M up to 10⁻⁸ M) on the release of [³H]dopamine synthesized continuously from [³H]tyrosine were examined in the caudate nucleus of halothane-anaesthetized cats implanted with push-pull cannulae. When used at a concentration of 10⁻⁸ M or 10⁻⁷ M,l-glutamate stimulated the release of [³H]dopamine from nerve terminals of the nigrostriatal dopamine neurons. This effect was still observed in the presence of tetrodotoxin (5 × 10⁻⁷ M) but it was antagonized by 2-amino 6-trifluoromethoxy benzothiazole (PK 26124) (10⁻⁵ M), an antagonist of glutamatergic transmission suggesting that the glutamatergic receptors involved were located on dopamine nerve terminals. While no significant change in the release of [³H]dopamine was observed with 10⁻⁶ Ml-glutamate, higher concentrations (from 10⁻⁵ M to 10⁻³ M) of the amino acid produced a longlasting reduction in the [³H]transmitter release. This latter effect was also antagonized by PK 26124 (10⁻⁵ M) but, unlike that observed with 10⁻⁸ Ml-glutamate, it did not persist in the presence of tetrodotoxin (5 × 10⁻⁷ M). On the contrary, a marked stimulation of the release of [³H]dopamine was seen in the presence of this neurotoxin. The reduction in the release of [³H]dopamine produced by 10⁻⁴ Ml-glutamate was also antagonized by bicuculline (10⁻⁵M) and moreover a marked stimulation of [³H]dopamine release took place in the presence of this γ-aminobutyric acid (GABA) antagonist. Therefore, high concentrations ofl-glutamate exerted an inhibitory presynaptic control on [³H]dopamine release which seemed to be indirect and mediated partly by GABAergic neurons. Since a sustained reduction in the spontaneous release of [³H]dopamine was seen in the presence of PK 26124, the corticostriatal glutamatergic neurons appeared to exert a tonic facilitatory presynaptic influence on dopamine release. This effect was important since it represented 40% of the tetrodotoxin-sensitive release of the [³H]transmitter.

The direct (stimulatory) and indirect (inhibitory) presynaptic controls on dopamine release mediated by corticostriatal glutamatergic fibres are discussed in light of previous findings and of the anatomical organization of the caudate nucleus.

References (52)

BenavidesJ. et al.
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of the excitatory amino acid neurotransmission. II. Biochemical properties
Neuropharmacology
(1985)
BernardiG. et al.
The action of acetylcholine andl-glutamic acid on rat caudate neurons
Brain Res.
(1976)
BouyerJ.J. et al.
Chemical and structural analysis of the relation between conical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum
Brain Res.
(1984)
BrownJ.R. et al.
The electrophysiology of dopamine (D2) receptors: a study of the actions of dopamine on corticostriatal transmission
Neuroscience
(1983)
CampochiaroP. et al.
GABA receptor binding in rat striatum: localization and effect of denervation
Brain Res.
(1977)
CheramyA. et al.
GABAergic processes involved in the control of dopamine release of the nigro-striatal dopaminergic neurons in the cat
Eur. J. Pharmac.
(1978)
ChesseletM.F.
Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis
Neuroscience
(1984)
FreundT.F. et al.
Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons with particular reference to dendritic spines
Neuroscience
(1984)
GarauL. et al.
Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum
Life Sci.
(1978)
GiorguieffM.F. et al.
Presynaptic effect ofl-glutamic acid on the release of dopamine in rat striatal slices
Neurosci. Lett.
(1977)

Giorguieff-ChesseletM.F. et al.

Attempts to localize the GABA receptors involved in the GABA-induced release of newlysynthesized dopamine in rat striatal slices

Brain Res.

(1979)

GodukhinO.V. et al.

Role of presynaptic dopamine receptors in regulation of the glutamatergic neurotransmission in the rat neostriatum

Neuroscience

(1984)

GraybielA.M.

Correspondence between the dopamine islands and striosomes of the mammalian striatum

Neuroscience

(1984)

HerrlingP.L. et al.

Iontophoretically applied dopamine depolarizes and hyperpolarizes the membrane of cat caudate neurons

Brain Res.

(1980)

KerkerianL. et al.

Topographic changes in high-affinity glutamate uptake in the cat red nucleus, substantia nigra, thalamus and caudate nucleus after lesions of sensorimotor cortical areas

Expl Neurol.

(1983)

KimJ.S. et al.

Effect of frontal cortex ablation on striatal glutamic acid level in rat

Brain Res.

(1977)

McGeerP.L. et al.

A glutamatergic corticostriatal path?

Brain Res.

(1977)

MitchellP.R. et al.

Modulation of striatal [³H]glutamic acid release by dopaminergic drugs

Life Sci.

(1980)

MizouleJ. et al.

2-Amino 6-trifluoromethoxy benzothiazole, a possible antagonist of the excitatory amino acid neurotransmission. I. Anticonvulsant properties

Neuropharmacology

(1985)

NieoullonA. et al.

Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat

Brain Res.

(1978)

NieoullonA. et al.

Inhibitory effects of dopamine on high-affinity glutamate uptake from rat striatum

Life Sci.

(1982)

NieoullonA. et al.

Presynaptic dopaminergic control of high affinity glutamate uptake in the striatum

Neurosci. Lett.

(1983)

ReubiJ.C. et al.

Glutamate release in vitro from corticostriatal terminals

Brain Res.

(1979)

RobertsP.J. et al.

Effects ofl-glutamate and related amino-acids upon the release of [³H]dopamine from rat striatal slices

Brain Res.

(1978)

RobertsP.J. et al.

Striatal glutamatergic function: modifications following specific lesions

Brain Res.

(1982)

RomoR. et al.

Distinct commissural pathways are involved in the enhanced release of dopamine induced in the contralateral caudate nucleus and substantia nigra by the unilateral application of GABA in the cat thalamic motor nuclei

Brain Res.

(1984)

Cited by (292)

Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate
2019, Pharmacology Biochemistry and Behavior
Citation Excerpt :
The CN is composed primarily of dopaminergic medium spiny neurons which have been shown to be critical for the acute effect of MPD (Karim et al. 2017; Claussen et al. 2015; Claussen et al. 2012; Kelly et al. 1975; Creese and Iversen 1974), but it is however unknown what role the CN plays in the reward/motive circuit's response to chronic MPD use. Glutaminergic signaling has been shown to modulate the long-term response between other reward/motive circuit nuclei (Pierce et al. 1996 & 1998; Pierce and Kalivas 1997; Reid and Berger 1996; Kalivas and Duffy 1998; Bell and Kalivas 1996; White et al., 1995a, b; Wolf 1998; Childress et al. 1999; Yang et al. 2006a, 2007a; Lee et al. 2008; Podet et al. 2010; Wanchoo et al. 2009, 2010; Hemby et al. 2005; Hnasko et al. 2012; Claussen et al. 2012; Jones and Dafny 2014), and it has been shown that glutamate also modulates dopaminergic signaling within the CN (Cheramy et al., 1986; White et al. 1995a; Reid et al. 1997; Wang et al. 1999; Hong et al. 2005; Gabriele et al. 2012; Lorenz et al. 2015; Leurquin-Sterk et al. 2018). While altered glutaminergic and dopaminergic signaling in the CN have been implicated in the development of behavioral markers of substance abuse disorders, the precise role of glutaminergic signaling in the CN in response to chronic psychostimulant use remains incompletely understood.
Methylphenidate (MPD) is a widely prescribed psychostimulant for the treatment of attention deficit hyperactivity disorder, and is growing in use as a recreational drug and academic enhancer. MPD acts on the reward/motive and motor circuits of the CNS to produce its effects on behavior. The caudate nucleus (CN) is known to be a part of these circuits, so a lesion study was designed to elucidate the role of the CN in response to acute and chronic MPD exposure. Five groups of n = 8 rats were used: control, sham CN lesions, non-specific electrolytic CN lesions, dopaminergic-specific (6-OHDA toxin) CN lesion, and glutaminergic-specific (ibotenic acid toxin) CN lesions. On experimental day (ED) 1, all groups received saline injections. On ED 2, surgeries took place, followed by a 5-day recovery period (ED 3–7). Groups then received six daily MPD 2.5 mg/kg injections (ED 9–14), then three days of washout with no injection (ED 15–17), followed by a re-challenge with the previous 2.5 mg/kg MPD dose (ED 18). Locomotive activity was recorded for 60 min after each injection by a computerized animal activity monitor. The electrolytic CN lesion group responded to the MPD acute and chronic exposures similarly to the control and sham groups, showing an increase in locomotive activity, i.e. sensitization. The dopaminergic-specific CN lesion group failed to respond to MPD exposure both acute and chronically. The glutaminergic-specific CN lesion group responded to MPD exposure acutely but failed to manifest chronic effects. This confirms the CN's dopaminergic system is necessary for MPD to manifest its acute and chronic effects on behavior, and demonstrates that the CN's glutaminergic system is necessary for the chronic effects of MPD such as sensitization. Thus, the dopaminergic and glutaminergic components of the CN play a significant role in differentially modulating the acute and chronic effects of MPD respectively.
Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: Setting the tone for reward processing
2012, Cell Reports
Dopamine plays a critical role in motor control, addiction, and reward-seeking behaviors, and its release dynamics have traditionally been linked to changes in midbrain dopamine neuron activity. Here, we report that selective endogenous cholinergic activation achieved via in vitro optogenetic stimulation of nucleus accumbens, a terminal field of dopaminergic neurons, elicits real-time dopamine release. This mechanism occurs via direct actions on dopamine terminals, does not require changes in neuron firing within the midbrain, and is dependent on glutamatergic receptor activity. More importantly, we demonstrate that in vivo selective activation of cholinergic interneurons is sufficient to elicit dopamine release in the nucleus accumbens. Therefore, the control of accumbal extracellular dopamine levels by endogenous cholinergic activity results from a complex convergence of neurotransmitter/neuromodulator systems that may ultimately synergize to drive motivated behavior.
New perspectives in glutamate and anxiety
2012, Pharmacology Biochemistry and Behavior
Citation Excerpt :
This process may be particularly relevant during synaptogenesis and neural circuitry plasticity (Konradi and Heckers, 2003). Glutamate not only exerts its effects through direct activation of glutamate neurotransmission but it also modulates the release of other neurotransmitters involved in stress-response, such as serotonin (Becquet et al., 1993; Cheramy et al., 1986), dopamine (Jedema and Moghddam, 1996), monoamines and GABA (Cortese and Phan, 2005). The hypothalamic–pituitary–adrenal (HPA) axis is the core structure regulating human stress response.
Anxiety and stress-related disorders, namely posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), obsessive–compulsive disorder (ODC), social and specific phobias, and panic disorder, are a major public health issue.
A growing body of evidence suggests that glutamatergic neurotransmission may be involved in the biological mechanisms underlying stress response and anxiety-related disorders. The glutamatergic system mediates the acquisition and extinction of fear-conditioning. Thus, new drugs targeting glutamatergic neurotransmission may be promising candidates for new pharmacological treatments. In particular, N-methyl-d-aspartate receptors (NMDAR) antagonists (AP5, AP7, CGP37849, CGP39551, LY235959, NPC17742, and MK-801), NMDAR partial agonists (DCS, ACPC), α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) antagonists (topiramate), and several allosteric modulators targeting metabotropic glutamate receptors (mGluRs) mGluR1, mGluR2/3, and mGluR5, have shown anxiolytic-like effects in several animal and human studies.
Several studies have suggested that polyamines (agmatine, putrescine, spermidine, and spermine) may be involved in the neurobiological mechanisms underlying stress-response and anxiety-related disorders. This could mainly be attributed to their ability to modulate ionotropic glutamate receptors, especially NR2B subunits.
The aim of this review is to establish that glutamate neurotransmission and polyaminergic system play a fundamental role in the onset of anxiety-related disorders. This may open the way for new drugs that may help to treat these conditions.
Antiglutamatergic drugs in the treatment of Parkinson's disease
2007, Handbook of Clinical Neurology
Citation Excerpt :
The antiglutamatergic agent riluzole (2‐amino‐6‐trifluoromrthoxy‐benzothiazole) is currently the only drug approved for the treatment of amyotrophic lateral sclerosis and its effect can only extend the survival of patients for a few months (Bensimon et al., 1994). Riluzole has multiple mechanisms of action: (1) inactivation of voltage‐dependent sodium channels (Benoit and Escande, 1991; Hubert et al., 1994); (2) non‐competitive blockade of postsynaptic excitatory amino acid receptors (Benavides et al., 1985; Debono et al., 1993); and (3) presynaptic inhibition of glutamate release (Cheramy et al., 1986, 1992). Preclinical data suggest that riluzole has a neuroprotective effect in animal models of PD (Boireau et al., 1994; Bezard et al., 1998).
This chapter focuses on antiglutamatergic drugs in the treatment of Parkinson's disease (PD). In the vertebrate brain, glutamate is the main excitatory neurotransmitter and mediates neurotransmission of most excitatory synapses. Glutamate-mediated synaptic transmission is essential for the normal functioning of the central nervous system. The ideal antiglutamatergic drug should largely be able to block the N-methyl-D-aspartate (NMDA) receptor in situations of excessive activation but without altering glutamatergic transmission during normal conditions. Amantadine is the only antiglutamatergic agent used in the management of PD patients and is particularly useful for the treatment of levodopa-induced dykinesias. Amantadine interacts with several different neurotransmitters systems and exhibits dopaminergic and anticholinergic properties along with antagonist activity of NMDA glutamatergic receptors. Amantadine exhibits mild antiparkinsonian effect and is more effective in the control of bradykinesia and rigidity than in tremor. It also exhibits neuroprotective properties in addition to its symptomatic effects. The chapter also describes some other antiglutamatergic drugs, namely memantine, dextromethorphan, budipine, and riluzole.
Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: Preliminary results of a dynamic [<sup>123</sup>I] IBZM SPECT study
2006, Journal of Psychiatric Research
Though there is considerable evidence that prefrontal repetitive transcranial magnetic stimulation (rTMS) exerts antidepressant effects, the neurobiological action of rTMS in patients with depression is poorly understood. Preclinical studies in animals and humans have demonstrated that prefrontal rTMS can induce dopamine release in mesostriatal and mesolimbic regions. We therefore investigated whether rTMS also modulates striatal dopaminergic neurotransmission in depressed patients using a dynamic [¹²³I] iodobenzamide (IBZM) single photon emission computed tomography (SPECT) approach. Five patients with a major depressive episode (DSM-IV) underwent an acute 10 Hz rTMS challenge with 3000 stimuli over the left dorsolateral prefrontal cortex during an [¹²³I] IBZM-SPECT bolus and constant infusion protocol. In four subjects the protocol was repeated after a three week rTMS standard treatment. Striatal IBZM binding to dopamine D₂ receptors was assessed with a region-of-interest (ROI) technique. The change in striatal IBZM binding after the rTMS challenge was regarded as measure of change in endogenous striatal dopamine.
Data of nine SPECT investigations showed a significant reduction by 9.6 ± 6.2% in IBZM binding to striatal dopamine D₂ receptors after rTMS challenge compared to baseline (p = 0.01, Wilcoxon test). In this preliminary study, the reduction of IBZM binding observed after rTMS challenge is suggestive of a release in endogenous dopamine induced by prefrontal rTMS. In future, this approach can be used to differentiate specific and non-specific reward-related effects of rTMS on dopaminergic neurotransmission.
Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice
2006, European Journal of Pharmacology
There are a number of reasons for believing that nitric oxide participates in motor control in the striatum. Therefore, effects of neuronal nitric oxide synthase inhibitor 7-nitroindazole (7-NI) were studied on the reserpine model of Parkinson's disease in Swiss and C57BL/6 mice using the open-field test. Mice received reserpine (1 mg/kg administered intraperitoneally). A significant hypolocomotion was observed 24 h and 48 h after reserpine injection. The treatment with 7-nitroindazole (25 mg/kg, administered intraperitoneally, 30 min after reserpine) attenuated reserpine-induced hypolocomotion 24 h and 48 h after the treatment in Swiss mice, but not completely in C57BL/6 mice. These results suggest that nitric oxide functions as an intercellular messenger in motor circuits in the brain. Moreover, our data suggests that the comparison of such mouse strains may provide information on genetic basis for strain differences in different sensitivity to these drugs.

View all citing articles on Scopus

^*: A.C. is a Rhoˆne-Poulenc Research fellow.

View full text

In vivo presynaptic control of dopamine release in the cat caudate nucleus—II. Facilitatory or inhibitory influence ofl-glutamate

Abstract

Neuropharmacology

Brain Res.

Brain Res.

Neuroscience

Brain Res.

Eur. J. Pharmac.

Neuroscience

Neuroscience

Life Sci.

Neurosci. Lett.

Brain Res.

Neuroscience

Neuroscience

Brain Res.

Expl Neurol.

Brain Res.

Brain Res.

Life Sci.

Neuropharmacology

Brain Res.

Life Sci.

Neurosci. Lett.

Brain Res.

Brain Res.

Brain Res.

Brain Res.